Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
The objective of this study was to develop chitosan (CS) nanoparticles (NPs) loaded with deferoxamine mesylate (DFO) for slow release of this iron-chelating drug. Drug nanoencapsulation was performed via ionic gelation of chitosan using sodium tripolyphosphate (TPP) as cross-linker. Nanoparticles wi...
Saved in:
Main Authors: | Maria Lazaridou (Author), Evi Christodoulou (Author), Maria Nerantzaki (Author), Margaritis Kostoglou (Author), Dimitra A. Lambropoulou (Author), Angeliki Katsarou (Author), Kostas Pantopoulos (Author), Dimitrios N. Bikiaris (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs
by: Aikaterini Karava, et al.
Published: (2020) -
Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study
by: Maria Grazia Piccioni, et al.
Published: (2020) -
Hepcidin Therapeutics
by: Angeliki Katsarou, et al.
Published: (2018) -
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity
by: Masanari Umemura, et al.
Published: (2017) -
Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017)